Douglas V. Faller, MD, PhD

Professor, Medicine

Douglas Faller
617.638.4173
72 E. Concord St Silvio Conte (K)

Other Positions

  • Active Staff Privileges, Hematology & Medical Oncology, Medicine, Boston Medical Center

Education

  • Harvard University, MD
  • Massachusetts Institute of Technology, PhD
  • Massachusetts Institute of Technology, BS

Publications

  • Published on 5/21/2018

    Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest New Drugs. 2018 May 21. PMID: 29781056.

    Read at: PubMed
  • Published on 5/10/2018

    Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV. Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review. Clin Lymphoma Myeloma Leuk. 2018 May 10. PMID: 29802009.

    Read at: PubMed
  • Published on 2/8/2018

    Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV. Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 Apr; 18(4):e157-e166. PMID: 29475821.

    Read at: PubMed
  • Published on 1/18/2018

    Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018 Mar 29; 131(13):1415-1424. PMID: 29348128.

    Read at: PubMed
  • Published on 1/5/2018

    Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V. Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid. 2018 Mar; 25(1):1-7. PMID: 29303358.

    Read at: PubMed
  • Published on 12/1/2017

    Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K. Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future. Biores Open Access. 2017; 6(1):169-181. PMID: 29291141.

    Read at: PubMed
  • Published on 10/1/2017

    Kodukula K, Faller DV, Harpp DN, Kanara I, Pernokas J, Pernokas M, Powers WR, Soukos NS, Steliou K, Moos WH. Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us Something. Biores Open Access. 2017; 6(1):123-132. PMID: 29098118.

    Read at: PubMed
  • Published on 4/11/2017

    Lin HM, Gao X, Cooke CE, Berg D, Labotka R, Faller DV, Seal B, Hari P. Disease burden of systemic light-chain amyloidosis: a systematic literature review. Curr Med Res Opin. 2017 Jun; 33(6):1017-1031. PMID: 28277869.

    Read at: PubMed
  • Published on 10/31/2016

    Faller DV, Castaneda SA, Zhou D, Vedamony M, Newburger PE, White GL, Kosanke S, Plett PA, Orschell CM, Boosalis MS, Perrine SP. An oral HemokineTM, a-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivo. Blood Cells Mol Dis. 2017 Mar; 63:1-8. PMID: 27888688.

    Read at: PubMed
  • Published on 10/20/2016

    Moos WH, Pinkert CA, Irwin MH, Faller DV, Kodukula K, Glavas IP, Steliou K. Epigenetic Treatment of Persistent Viral Infections. Drug Dev Res. 2017 Feb; 78(1):24-36. PMID: 27761936.

    Read at: PubMed

View 268 more publications: View full profile at BUMC

View all profiles